Management of anemia in chronic kidney disease
نویسندگان
چکیده
Anemia is the most common complication of chronic kidney disease (CKD) associated with reduced quality life and increased morbidity mortality. The purpose this review was to discuss management anemia in CKD. following topics are considered: prevalence anemia, symptoms, impact CKD, diagnosis, iron replacement therapy, erythropoiesis-stimulating agents.
منابع مشابه
Management of Anemia in Chronic Kidney Disease: Revisited
Chronic Kidney Disease (CKD) leads to a wide range of systemic derangements. Anemia is a common complication among CKD patients.1 Anemia begins to manifest when GFR falls below 60ml/min/1.73 m2 (Stage III).2 In our previous review published in 1999,3 we did an effort to explain the basic pathophysiology and elaborate various treatment modalities for treatment of anemia. Management of anemia in ...
متن کاملAnemia of chronic kidney disease.
A nemia is a common complication in patients with chronic kidney disease (CKD). Recombinant erythropoietin (epoetin) has been the most important advance in treating this anemia. Erythropoietin was approved by the Food and Drug Administration (FDA) in 1989. Although the initial goal of treating CKD anemia with epoetin was to prevent blood transfusions, evidence from prospective studies also demo...
متن کاملAnemia management in chronic kidney disease: bursting the hemoglobin bubble.
Until the approval of recombinant erythropoietin therapy in 1989, many patients receiving dialysis were severely anemic and needed transfusions to maintain a hemoglobin level greater than 70 g/L. Recombinant erythropoietin was greeted as a panacea for anemia in chronic kidney disease (CKD) and was approved for use with considerable fanfare, relatively little clinical trial data, and few reserva...
متن کاملChronic Kidney Disease Anemia Management: What Should Be Done?
A transition in the approach to anemia management in nephrology occurred when randomized trials demonstrated that higher hemoglobin targets do not result in better outcomes and may arguably cause harm. Contradicting the speculative conclusions drawn based on earlier observational data, this has resulted in hypotheses regarding the cause of these seemingly disparate but substantively similar mes...
متن کاملChronic Kidney Disease Anemia Management: What Should Be Done?
A transition in the approach to anemia management in nephrology occurred when randomized trials demonstrated that higher hemoglobin targets do not result in better outcomes and may arguably cause harm. Contradicting the speculative conclusions drawn based on earlier observational data, this has resulted in hypotheses regarding the cause of these seemingly disparate but substantively similar mes...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Po?ki
سال: 2021
ISSN: ['2307-1265', '2307-1257']
DOI: https://doi.org/10.22141/2307-1257.10.2.2021.234324